Skip to main content
. 2013 Jun 12;7(5-6):E411–E416. doi: 10.5489/cuaj.478
Patients with newly diagnosed low- or intermediate-risk prostate cancer who require or choose active treatment and are not considering or are not suitable for active surveillance.

Low-risk defined as: Intermediate-risk defined as:
• PSA <10 ng/mL • PSA ≥ 10 ng/mL, but <20 ng/mL
• clinical stage T1c-T2a • or clinical stage T2b-T2c
• Gleason score <7 • or Gleason score =7

PSA: prostate-specific antigen.